ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

1:00PM-2:30PM: Abstract Number: 0800

Associations of Rheumatoid Arthritis Polygenic Risk with Age at Onset, Serostatus, and Interstitial Lung Disease

Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: Breathe: RA-ILD

1:00PM-2:30PM: Abstract Number: 0825

Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator (BRAVO): 6-month Outcomes of a Longitudinal Cohort Study

Abstracts: Vasculitis – ANCA-Associated I

1:00PM-2:30PM: Abstract Number: 0790

CoLchicine for Treatment of OsteoArthritis of the Knee: Clinical Outcomes from a 90-day Double-Blind, Placebo-Controlled Study

Abstracts: Osteoarthritis – Clinical Trials

1:00PM-2:30PM: Abstract Number: 0778

Comprehensive Immune Profiling of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Patients with Autoimmune Disease

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease I

1:00PM-2:30PM: Abstract Number: 0808

Confirmation of Second Trimester Trophoblast Transport of Maternal Anti-SSA/Ro52 and 60kD Autoantibodies in Cardiac Neonatal Lupus: Implications for FcRn Blockade

Abstracts: Reproductive Issues in Rheumatic Disorders

1:00PM-2:30PM: Abstract Number: 0780

Deep B Cell Tissue Depletion Following Anti-CD19 CART Cells Therapy

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease I

1:00PM-2:30PM: Abstract Number: 0818

Defining BASDAI Cut-offs for Disease Activity States in Axial Spondylarthritis – Results from the EuroSpA Collaboration

Abstracts: SpA Including PsA – Diagnosis, Manifestations, & Outcomes I

1:00PM-2:30PM: Abstract Number: 0796

Development and Evaluation of Machine Learning Prediction Models for Hospitalizations Due to Opioid-Related Harms Among New Users with Rheumatic and Musculoskeletal Diseases

Abstracts: Pain in Rheumatic Disease Including Fibromyalgia

1:00PM-2:30PM: Abstract Number: 0802

Disease Activity Is Strongly Associated with RA-related Lung Disease and Interstitial Lung Disease in Early RA: Results from a Multicenter, Prospective Cohort Study

Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: Breathe: RA-ILD

1:00PM-2:30PM: Abstract Number: 0816

Distinct Transcript and Protein Dysregulation Patterns in Dermatomyositis and Systemic Lupus Erythematosus

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: Omics

1:00PM-2:30PM: Abstract Number: 0828

Efficacy of Eosinophil-Targeting Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis in the Phase 3 MANDARA Trial

Abstracts: Vasculitis – ANCA-Associated I

1:00PM-2:30PM: Abstract Number: 0787

Efficacy of Intra-Articular Hyaluronic Acid Injection for Nonsurgical Management of Carpometacarpal Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Clinical Trials

Abstracts: Osteoarthritis – Clinical Trials

1:00PM-2:30PM: Abstract Number: 0807

Evaluating Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus (SLE) and SLE Subgroups: Additional Risks Associated with Cardiovascular Events

Abstracts: Reproductive Issues in Rheumatic Disorders

1:00PM-2:30PM: Abstract Number: 0785

Exploring the Link Between Atgl-Dependent Lipolysis and Dermal Fibrosis in Systemic Sclerosis

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science

1:00PM-2:30PM: Abstract Number: 0786

First Analyses of Transcriptomic Changes in the Skin of SSc Patients upon CD19-targeting CAR T Cell Therapy

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].